NewAmsterdam Ptb Ratio from 2010 to 2024

NAMSW Stock   9.06  0.63  6.50%   
NewAmsterdam Pharma PTB Ratio yearly trend continues to be fairly stable with very little volatility. PTB Ratio is likely to outpace its year average in 2024. PTB Ratio is price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on NewAmsterdam Pharma's equity relative to its net asset value. View All Fundamentals
 
PTB Ratio  
First Reported
2010-12-31
Previous Quarter
2.87894574
Current Value
3.02
Quarterly Volatility
20.80228522
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Tax Provision of 28.4 K, Net Interest Income of 3.6 M or Interest Income of 11.8 M, as well as many indicators such as Price To Sales Ratio of 68.31, Dividend Yield of 0.0 or PTB Ratio of 3.02. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.
  
Check out the analysis of NewAmsterdam Pharma Correlation against competitors.
For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.

Latest NewAmsterdam Pharma's Ptb Ratio Growth Pattern

Below is the plot of the Ptb Ratio of NewAmsterdam Pharma over the last few years. It is price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value. NewAmsterdam Pharma's PTB Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewAmsterdam Pharma's overall financial position and show how it may be relating to other accounts over time.
Ptb Ratio10 Years Trend
Slightly volatile
   Ptb Ratio   
       Timeline  

NewAmsterdam Ptb Ratio Regression Statistics

Arithmetic Mean(30.97)
Coefficient Of Variation(67.16)
Mean Deviation17.77
Median(43.09)
Standard Deviation20.80
Sample Variance432.74
Range46.1452
R-Value0.77
Mean Square Error190.98
R-Squared0.59
Significance0.0008
Slope3.57
Total Sum of Squares6,058

NewAmsterdam Ptb Ratio History

2024 3.02
2023 2.88
2022 0.4
2021 3.06

About NewAmsterdam Pharma Financial Statements

NewAmsterdam Pharma investors use historical fundamental indicators, such as NewAmsterdam Pharma's Ptb Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NewAmsterdam Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
PTB Ratio 2.88  3.02 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.